Moreover, based on the frequent occurrence of CRS, which includes TNF-α as one of the predominant proinflammatory cytokines, during severe courses of COVID-19, it was speculated that TNF-α blockers such as infliximab may be an effective treatment of CRS [71]. This evidence concerns the gene TNF and congenital rubella syndrome.